1
|
Jin N, Xu Y, Wang S, Sun C, Yan X, Yang F, Liang Y, Chen W, Huang X. Inetetamab combined with pyrotinib and oral vinorelbine for patients with human epidermal growth factor receptor 2 positive advanced breast cancer: A single-arm phase 2 clinical trial. Cancer Pathog Ther 2024; 2:31-37. [PMID: 38328709 PMCID: PMC10846324 DOI: 10.1016/j.cpt.2023.10.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 10/16/2023] [Accepted: 10/22/2023] [Indexed: 02/09/2024]
Abstract
Background Human epidermal growth factor receptor 2 (HER2)-targeted agents have significantly improved the outcomes of patients with HER2-positive breast cancer; however, a large proportion of patients still develop resistance to trastuzumab. In this study, we investigated the efficacy and safety of inetetamab, another anti-HER2 antibody, combined with pyrotinib and oral vinorelbine in patients with HER2-positive advanced breast cancer so as to provide new ideas for the treatment. Methods In this prospective, single-arm, phase 2 trial, patients with HER2-positive advanced breast cancer with disease progression after trastuzumab were recruited. Patients received a combination of inetetamab (loading dose of 8 mg/kg and subsequent doses of 6 mg/kg intravenously once every 3 weeks), pyrotinib (400 mg orally once daily), and vinorelbine (60 mg/m2 orally once weekly) until disease progression or intolerable toxicity. The primary endpoint was progression-free survival (PFS). The secondary endpoints included objective response rate (ORR), overall survival (OS), disease control rate (DCR), and safety. Results Between February 13, 2022 and December 25, 2022, 30 patients were screened and enrolled in this study. The median age of the patients at enrollment was 54 years, 12 patients (40.0 %) had hormone-receptor-positive disease and 23 patients (76.7 %) had visceral metastasis. The median PFS was 8.63 months (95 % confidence interval [CI] 4.15-13.12 months). The median OS was not reached. The ORR was 53.3 % (16/30) and the DCR was 96.7 % (29/30). The most common Grade III/IV adverse events were leukopenia (n = 5, 16.7 %), neutropenia (n = 4, 13.3 %), and diarrhea (n = 3, 10 %). No treatment-related serious adverse events or deaths occurred. Conclusions The combination regimen of inetetamab, pyrotinib, and oral vinorelbine showed encouraging efficacy and favorable safety in patients with HER2-positive advanced breast cancer and could be considered as an alternative treatment option for the patients. Trial registration No.NCT05823623; https://www.clinicaltrials.gov/.
Collapse
Affiliation(s)
- Nan Jin
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Yi Xu
- Department of Pathology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Siqi Wang
- Radiology Department, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Chunxiao Sun
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Xueqi Yan
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Fan Yang
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Yan Liang
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| | - Weiwei Chen
- Department of Oncology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu 210000, China
| | - Xiang Huang
- Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China
| |
Collapse
|
2
|
Bergen E, Berghoff AS, Rudas M, Dubsky P, De Vries C, Sattlberger C, Mader RM, Zagouri F, Sparber C, Fitzal F, Gnant M, Rottenfusser A, Zielinski CC, Preusser M, Steger GG, Bartsch R. Taxanes Plus Trastuzumab Compared To Oral Vinorelbine Plus Trastuzumab in HER2-Overexpressing Metastatic Breast Cancer. ACTA ACUST UNITED AC 2015; 9:344-8. [PMID: 25759615 DOI: 10.1159/000368330] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
BACKGROUND This retrospective analysis was planned as a direct comparison of taxanes plus trastuzumab to the less toxic combination of oral vinorelbine (OV) plus trastuzumab as a first-line therapy for metastatic HER2-positive breast cancer. PATIENTS AND METHODS Patients (n = 76) receiving either taxanes (group A) or OV (group B) in combination with trastuzumab were identified from a breast cancer database. Progression-free survival (PFS) was defined as the primary study endpoint; secondary endpoints were overall survival (OS), response rate (RR), incidence of brain metastases, and brain metastases-free survival (BMFS). RESULTS 36 patients received taxanes and 40 patients OV in combination with trastuzumab. At a median follow-up of 47.5 months, median PFS was 7 months (group A) and 9 months in group B (log-rank; non-significant), respective numbers for OS were 49 and 59 months (p = 0.033). The incidence of brain metastases did not differ significantly between the 2 treatment groups, whereas BMFS was significantly longer in patients receiving OV. CONCLUSIONS OV plus trastuzumab yielded similar results in terms of PFS and RR and was superior in terms of OS and BMFS. These results add to the growing body of evidence that vinorelbine is a viable alternative to taxanes in HER2-positive metastatic breast cancer.
Collapse
Affiliation(s)
- Elisabeth Bergen
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| | - Anna S Berghoff
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| | - Margaretha Rudas
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Pathology, Medical University of Vienna, Austria
| | - Peter Dubsky
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Surgery, Medical University of Vienna, Austria
| | | | | | - Robert M Mader
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| | - Flora Zagouri
- Department of Clinical Therapeutics, Alexandra Hospital, School of Medicine, University of Athens, Greece
| | | | - Florian Fitzal
- Department of Surgery, KH Barmherzigen Schwestern Linz, Austria
| | - Michael Gnant
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Surgery, Medical University of Vienna, Austria
| | - Andrea Rottenfusser
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Radiotherapy, Medical University of Vienna, Austria
| | - Christoph C Zielinski
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| | - Matthias Preusser
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| | - Guenther G Steger
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| | - Rupert Bartsch
- Comprehensive Cancer Center Vienna, Medical University of Vienna, Austria ; Department of Medicine 1, Clinical Division of Oncology, Medical University of Vienna, Austria
| |
Collapse
|
3
|
Heinemann V, Di Gioia D, Vehling-Kaiser U, Harich HD, Heinrich B, Welt A, Ziske C, Deutsch G, Pihusch R, Kölbl H, Hegewisch-Becker S, Michl M, Stemmler HJ. A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 2010; 22:603-608. [PMID: 20724574 DOI: 10.1093/annonc/mdq409] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To evaluate the efficacy and safety of oral and i.v. vinorelbine plus trastuzumab as first-line regimen in a patient-convenient application for human epidermal growth factor receptor 2 (HER2)-overexpressing patients with metastatic breast cancer. PATIENTS AND METHODS Forty-two women were enrolled in a multicenter study. The patients received i.v. vinorelbine at a dose of 25 mg/m(2) on day 1 followed by oral vinorelbine at a dose of 60 mg/m(2) on days 8 and 15 in a 3-week cycle. Standard dose trastuzumab was given at 3-week intervals. RESULTS Complete response was observed in 7 patients (18.9%) and partial response in 19 patients (51.4%), for an overall response rate of 70.3% [95% confidence interval (CI) 53.0-84.1]. The disease control rate reached 91.9% (95% CI 78.1-98.3). The median time to progression was 9.3 months, while median overall survival reached 35.6 months. Hematological and non-hematological toxic effects were acceptable with grade 3-4 leukopenia of 14% and neutropenia of 38%; cardiac toxicity did not reach the level of clinical relevance. CONCLUSION The combination of i.v. and oral vinorelbine plus trastuzumab demonstrates high activity and good tolerability in first-line treatment of HER2-overexpressing metastatic breast cancer. In addition, it offers convenience for the patients with only one i.v. treatment every 3 weeks.
Collapse
Affiliation(s)
- V Heinemann
- Medical Department III, University of Munich, Munich.
| | - D Di Gioia
- Medical Department III, University of Munich, Munich
| | | | | | | | - A Welt
- Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen
| | - C Ziske
- Oncological Practice, Troisdorf
| | - G Deutsch
- Department of Gynecology, Diakonissenkrankenhaus Karlsruhe, Karlsruhe
| | | | - H Kölbl
- Department of Gynecology, University of Mainz, Mainz
| | | | - M Michl
- Medical Department III, University of Munich, Munich
| | - H J Stemmler
- Medical Department III, University of Munich, Munich
| |
Collapse
|
4
|
Iorfida M, Bagnardi V, Balduzzi A, Dellapasqua S, Cardillo A, Luini A, Intra M, Minchella I, Veronesi P, Viale G, Goldhirsch A, Colleoni M. Preoperative therapy with trastuzumab and oral vinorelbine (± endocrine therapy) in patients with HER2-positive breast cancer. Breast 2010; 19:128-32. [DOI: 10.1016/j.breast.2009.12.011] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2009] [Revised: 11/20/2009] [Accepted: 12/27/2009] [Indexed: 11/20/2022] Open
|
5
|
Redana S, Donadio M, Nolè F, Jacomuzzi ME, Beano A, Martinello R, Sapino A, Viale G, Aglietta M, Montemurro F. Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer 2010; 10:28. [PMID: 20122160 PMCID: PMC2835645 DOI: 10.1186/1471-2407-10-28] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2009] [Accepted: 02/01/2010] [Indexed: 11/17/2022] Open
Abstract
BACKGROUND Combinations of trastuzumab with either docetaxel or vinorelbine are considered valuable treatment options for HER2-positive metastatic breast cancer patients. We performed a retrospective comparison of the clinical outcomes associated with either one of these combinations. METHODS From a multi-institutional database we retrieved 179 patients treated with either docetaxel or vinorelbine plus trastuzumab as first-line therapy for HER2-positive advanced breast cancer. RESULTS Docetaxel-trastuzumab was superior to vinorelbine-trastuzumab in terms of response rate (RR: 77 vs 57%, p = 0.01) and median overall survival (OS: 35 vs 23 months, p = 0.04), but not in median time to progression (TTP: 12 vs 10 months, p = 0.53). At multivariate analysis, type of treatment was not associated with TTP but was an independent predictor of OS, with a significant reduction in the risk of death in favor of docetaxel-trastuzumab (HR 0.474, 95% IC 0,303-0.742, p < 0.01). CONCLUSION Docetaxel or vinorelbine, when combined with trastuzumab, provide excellent rates of tumor control in patients with previously untreated HER2-positive advanced breast cancer. Docetaxel may offer some advantage in terms of response rate and resulted in a significantly prolonged overall survival, which, because of the retrospective design of our study, deserves further investigation in prospective trials.
Collapse
Affiliation(s)
- Stefania Redana
- Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo Italy
| | - Michela Donadio
- Molinette Hospital, Centro Oncologico Subalpino (COES), Turin, Italy
| | - Franco Nolè
- European Institute of Oncology (IEO), Department of Medical Oncology, Milan, Italy
| | | | - Alessandra Beano
- Molinette Hospital, Centro Oncologico Subalpino (COES), Turin, Italy
| | - Rossella Martinello
- Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo Italy
| | - Anna Sapino
- University of Turin, Department of Biomedical Sciences and Human Oncology, Turin, Italy
| | - Giuseppe Viale
- European Institute of Oncology (IEO), Division of Surgical Pathology and Laboratory Medicine, Milan, Italy
| | - Massimo Aglietta
- Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo Italy
| | - Filippo Montemurro
- Institute for Cancer Research and Treatment, Division of Medical Oncology, Candiolo Italy
| |
Collapse
|
6
|
Petrelli F, Barni S. Oral vinorelbine: its role in advanced breast cancer pre-treated with anthracycline and taxane chemotherapies. Oncol Rev 2010. [DOI: 10.1007/s12156-010-0038-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
7
|
Abstract
Renal cell carcinoma (RCC) is currently one of the most treatment-resistant malignancies and affects approximately three in 10,000 people. The impact of this disease produces about 31,000 new cases in the United States per year; and 12,000 people in the United States alone die from RCC annually. Although several treatment strategies have been investigated for RCC, this cancer continues to be a therapeutic challenge. For this reason, the aim of our study is to develop a more effective combinational therapy to treat advanced RCC. We examined the effect of vinorelbine on the signalling pathways of two human renal cancer cell lines (A498 and 786-O) and also examined the in vivo effect of vinorelbine treatment alone and vinorelbine in combination with the anti-VEGF antibody 2C3 on A498 and 786-O tumour growth in nude mice. Tumour angiogenesis was measured by vWF staining, and apoptosis was determined by the TUNEL assay. We observed a significant tumour growth inhibition when using a combinational therapy of anti-VEGF antibody 2C3 and vinorelbine in both A498 and 786-O tumour-bearing mice. The results suggest a breakthrough treatment for advanced RCC.
Collapse
Affiliation(s)
- Sutapa Sinha
- Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
| | | | | | | | | |
Collapse
|
8
|
Schilling G, Bruweleit M, Harbeck N, Thomssen C, Becker K, Hoffmann R, Villena C, Schütte M, Hossfeld DK, Bokemeyer C, de Wit M. Phase II trial of vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. A prospective, open label, non-controlled, multicenter phase II trial (to investigate efficacy and safety of this combination chemotherapy). Invest New Drugs 2008; 27:166-72. [PMID: 18696011 DOI: 10.1007/s10637-008-9166-8] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2008] [Accepted: 07/21/2008] [Indexed: 12/14/2022]
Abstract
The purpose of this study was to evaluate the efficacy (progression free survival (PFS) and response rate) and safety of vinorelbine and trastuzumab combination chemotherapy in patients with HER2-overexpressing, metastatic breast cancer as a first line chemotherapy regimen. Patients with histologically confirmed, HER2-positive (immunohistochemistry (ICH) 3+, or 2+ and FISH+) metastatic breast cancer who had nor received prior vinorelbine or anti-HER2 therapy in the adjuvant setting, received at least eight weeks of vinorelbine i.v. (25 mg/g weekly) and trastuzumab (4 mg/kg on day 1 followed by 2 mg/kg weekly). Forty-one women from six participating centers were enrolled into the trial. The overall response rate, was 43.9% (18 of 41 patients), (CI 28-60.3%), 30% of patients were progression free after 1 year. Four patients reached complete remission, 14 partial remission and five had stable disease for at least 18 weeks. Six patients developed primary progression. 35 patients (85%) experienced progression after a median time of 235 days. Therapy was in general well-tolerated. There were two CTC grade 4 infusion syndromes and two patients experienced cardiotoxicity at least grade 2. This phase II trial of vinorelbine and trastuzumab demonstrated an effective and well-tolerated regimen with a favourable safety profile.
Collapse
Affiliation(s)
- G Schilling
- Onkologisches Zentrum, II. Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Montemurro F, Redana S, Nolè F, Donadio M, Jacomuzzzi ME, Valabrega G, Viale G, Sapino A, Aglietta M. Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study. BMC Cancer 2008; 8:209. [PMID: 18652678 PMCID: PMC2503990 DOI: 10.1186/1471-2407-8-209] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2008] [Accepted: 07/24/2008] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The vinka-alkaloyd vinorelbine is a potentially valuable treatment in patients with HER2-positive, trastuzumab-resistant advanced breast cancer. We sought to document the clinical activity of vinorelbine-based salvage treatments in this clinical setting. METHODS We analyzed a cohort of 424 consecutive women receiving trastuzumab-based therapy for HER2-positive advanced breast cancer. Of these, 299 were identified as progressing during the initial trastuzumab-based treatment, and 77 received vinorelbine-based therapy as first salvage treatment. Central review of pathological specimens revealed that 70 patients had HER2-amplification detected by FISH. For these patients we determined overall response rate (ORR = complete-CR + partial-PR) and clinical benefit (CB = CR+PR+ Stable disease lasting at least 6 months), time to progression (TTP) and overall survival (OS) from the initiation of vinorelbine-based salvage therapy. RESULTS In 60 patients who were evaluable for tumor response, ORR and CB rates were 28% (95% C.I. 18%-41%) and 50% (95% C.I. 38%-62%), respectively. Median follow-up from the initiation of salvage therapy was 15 months (range 1-63 months). Median TTP and OS were 7.1 months (95% C.I. 6.6-7.7 months) and 21 months (95% C.I. 14.3-27.7 months), respectively. No differences in clinical outcomes were observed according to whether vinorelbine was administered as a single agent or in combination with other cytostatics, or whether trastuzumab was stopped or continued beyond disease progression. CONCLUSION our findings suggests that vinorelbine-based combinations are active and should be further evaluated in studies conducted in trastuzumab-resistant patients, including those evaluating newer HER2-targeting agents.
Collapse
Affiliation(s)
- Filippo Montemurro
- Divisione di Oncologia Medica, AO Ordine Mauriziano/Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Liu Y, Lu W, Guo J, Du J, Li T, Wu J, Wang G, Wang J, Zhang X, Zhang Q. A potential target associated with both cancer and cancer stem cells: A combination therapy for eradication of breast cancer using vinorelbine stealthy liposomes plus parthenolide stealthy liposomes. J Control Release 2008; 129:18-25. [DOI: 10.1016/j.jconrel.2008.03.022] [Citation(s) in RCA: 96] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2007] [Revised: 03/06/2008] [Accepted: 03/20/2008] [Indexed: 11/22/2022]
|
11
|
Hennig IM, Twelves C. Loading doses for costly cancer biologicals: a cause for concern or tilting at windmills? Eur J Cancer 2008; 44:1493-6. [PMID: 18515087 DOI: 10.1016/j.ejca.2008.04.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2008] [Accepted: 04/10/2008] [Indexed: 11/26/2022]
Abstract
The emergence of novel, effective but expensive biological therapies is significantly improving outcomes for many patients with cancer, but also substantially increasing treatment costs. Monoclonal antibodies with long half-lives have often been developed using loading doses to hasten the achievement of a therapeutic dose. Although the benefits of loading doses have not been proven, we caution against abandoning this practice on uncertain theoretical grounds. Rather, the issue of loading doses should be seen in the broader context of how best to define the optimal dose, schedule and duration of treatment through novel clinical trial designs.
Collapse
Affiliation(s)
- Ivo M Hennig
- Section of Oncology and Clinical Research, Cancer Research UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds & St James's University Hospital, 4th Floor, Bexley Wing, Leeds LS9 7TF, UK
| | | |
Collapse
|